weight loss drug news today glp-1 october 2025 Rhode Island considers ending Medicaid coverage of drugs for • Rhode Island Current Older Americans Quit Weight Loss

By identifying patients at risk for side effects before treatment begins, we can match the right patient to the right therapy, increase real-world adherence, and dramatically improve clinical trial efficiency through smarter patient selection

Several GLP-1 agonists have FDA approval for other indications that may overlap with BED patient populations: Semaglutide (Wegovy) and liraglutide (Saxenda) are approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity Semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro) are approved for type 2 diabetes management Tirzepatide (Zepbound) is approved for chronic weight management When clinicians prescribe GLP-1 agonists for BED, this constitutes off-label use a legal and common practice in medicine when evidence suggests potential benefit and approved treatments are inadequate

If you have not responded to other weight-loss medications or have plateaued in your weight loss, seeking enrollment in a clinical trial for retatrutide may be a great option for you

Vegetables and fiber Vegetables provide essential vitamins, minerals, and fiber but the way you prepare them matters, especially in the first weeks of treatment